Title

Enhanced Systemic Bioavailability of Curcumin Through Transmucosal Administration of a Novel Microgranular Formulation

Authors

Brian Latimer, Feist-Weiller Cancer Center, Louisiana State University Health Sciences Center, Shreveport, LA, U.S.A. Department of Pharmacology, Toxicology and Neuroscience, Louisiana State University Health Sciences Center, Shreveport, LA, U.S.A.
Oleksandr Ekshyyan, Feist-Weiller Cancer Center, Louisiana State University Health Sciences Center, Shreveport, LA, U.S.A. Department of Otolaryngology-Head and Neck Surgery, Louisiana State University Health Sciences Center, Shreveport, LA, U.S.A.
Neil Nathan, Feist-Weiller Cancer Center, Louisiana State University Health Sciences Center, Shreveport, LA, U.S.A. Department of Pharmacology, Toxicology and Neuroscience, Louisiana State University Health Sciences Center, Shreveport, LA, U.S.A.
Tara Moore-Medlin, Feist-Weiller Cancer Center, Louisiana State University Health Sciences Center, Shreveport, LA, U.S.A. Department of Otolaryngology-Head and Neck Surgery, Louisiana State University Health Sciences Center, Shreveport, LA, U.S.A.
Xiaohua Rong, Feist-Weiller Cancer Center, Louisiana State University Health Sciences Center, Shreveport, LA, U.S.A. Department of Otolaryngology-Head and Neck Surgery, Louisiana State University Health Sciences Center, Shreveport, LA, U.S.A.
Xiaohui Ma, Feist-Weiller Cancer Center, Louisiana State University Health Sciences Center, Shreveport, LA, U.S.A. Department of Otolaryngology-Head and Neck Surgery, Louisiana State University Health Sciences Center, Shreveport, LA, U.S.A.
Alok Khandelwal, Feist-Weiller Cancer Center, Louisiana State University Health Sciences Center, Shreveport, LA, U.S.A. Department of Otolaryngology-Head and Neck Surgery, Louisiana State University Health Sciences Center, Shreveport, LA, U.S.A.
Hunter T. Christy, Department of Otolaryngology-Head and Neck Surgery, Louisiana State University Health Sciences Center, Shreveport, LA, U.S.A.
Fleurette Abreo, Department of Pathology, Louisiana State University Health Sciences Center, Shreveport, LA, U.S.A.
Gloria McClure, Department of Pediatrics, Louisiana State University Health Sciences Center, Shreveport, LA, U.S.A.
John A. Vanchiere, Department of Pediatrics, Louisiana State University Health Sciences Center, Shreveport, LA, U.S.A.
Gloria Caldito, Department of Biometry, Louisiana State University Health Sciences Center, Shreveport, LA, U.S.A.
Tammy Dugas, Department of Comparative Biomedical Sciences, Louisiana State University School of Veterinary Medicine, Baton Rouge, LA, U.S.A.
Kenneth McMartin, Department of Pharmacology, Toxicology and Neuroscience, Louisiana State University Health Sciences Center, Shreveport, LA, U.S.A.
Timothy Lian, Feist-Weiller Cancer Center, Louisiana State University Health Sciences Center, Shreveport, LA, U.S.A. Department of Otolaryngology-Head and Neck Surgery, Louisiana State University Health Sciences Center, Shreveport, LA, U.S.A.
Vikas Mehta, Feist-Weiller Cancer Center, Louisiana State University Health Sciences Center, Shreveport, LA, U.S.A. Department of Otolaryngology-Head and Neck Surgery, Louisiana State University Health Sciences Center, Shreveport, LA, U.S.A.
Cherie-Ann O. Nathan, Feist-Weiller Cancer Center, Louisiana State University Health Sciences Center, Shreveport, LA, U.S.A. Department of Otolaryngology-Head and Neck Surgery, Louisiana State University Health Sciences Center, Shreveport, LA, U.S.A. cnatha@lsuhsc.edu.

Document Type

Article

Publication Date

12-1-2015

Abstract

BACKGROUND/AIM: Curcumin is a promising nutraceutical for chemoprevention of head and neck squamous cell carcinoma (HNSCC). Capsular formulations of curcumin demonstrate low systemic bioavailability. We aimed to determine if curcumin levels were higher in healthy volunteers and cancer patients with microgranular curcumin that allows for transmucosal absorption and identify a consistent biomarker. PATIENTS AND METHODS: Eight healthy volunteers and 15 HNSCC patients completed the trials. Serum levels of curcumin were measured by HPLC. Biological activity of curcumin was assessed with Multiplex Immunoassay and immunohistochemistry. RESULTS: We achieved higher serum levels of curcumin compared to trials using capsular formulation. In cancer patients a significant decrease in expression of fibroblast growth factor-2 (FGF-2) in post-biopsy samples and decreased serum levels of FGF-2, granulocyte macrophage colony-stimulating factor (GM-CSF) and interleukin-17 (IL-17) (p<0.05) was observed. CONCLUSION: Transmucosal administration of microgranular curcumin leads to enhanced curcumin bioavailability that is associated with significant biological effects.

Publication Source (Journal or Book title)

Anticancer research

First Page

6411

Last Page

8

This document is currently not available here.

COinS